Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Hair loss treatments like finasteride and minoxidil are becoming more mainstream, with younger men starting early to prevent baldness. Increased sharing of transformations online and proactive approaches by Gen Z are contributing to noticeable changes.

Some hair loss may be linked to chromosome 20, which isn't affected by DHT blockers like finasteride. Treatments like minoxidil, microneedling, and genetic testing are suggested, but their effectiveness for this type of hair loss is uncertain.

The conversation discusses whether Harry Styles had a hair transplant, with opinions divided on whether he changed his hairstyle or underwent a procedure. It also touches on the use of medication and surgery as treatments for hair loss.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

Hair cloning might be available in 10-15 years, but current and upcoming treatments like finasteride, dutasteride, and new drugs like g20029 may make it unnecessary. Advances in hair regrowth technology and treatments are expected to be more cost-effective and accessible.

A user shared their positive experience with hair regrowth using minoxidil, hormone replacement therapy, and cyproterone acetate during their male-to-female transition. Another user discussed their successful hair transplant after transitioning and using finasteride, highlighting the challenges of hair loss and regrowth during transition.

The conversation is about a user interested in participating in hair cloning clinical trials due to their fine hair and previous positive experience with clinical trials. They are seeking information on how to volunteer for such trials.

Turkey is a popular destination for hair transplants due to lower costs, but quality varies, and many clinics are scams. It's crucial to research and select reputable clinics to ensure good results.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

Stem cell injections for hair loss are being discussed, with concerns about their effectiveness and high cost. The user is considering this treatment before opting for a hair transplant.

KPV, a peptide patented by L'Oreal, may promote hair growth and reduce hair loss by extending the anagen phase and has anti-inflammatory properties. It could be combined with treatments like minoxidil for enhanced effects.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

New hair loss treatments like stem cells, hair cloning, and gt20029 are unlikely to be available in the next 5-10 years, with some trials possibly starting by 2026. Current treatments like Minoxidil and Finasteride have been used for decades, and new developments depend on funding and successful trials.

Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.

Verteporfin reduces scar tissue in hair transplants but doesn't significantly regrow hair follicles. More testing is needed to determine its effectiveness.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

A 22-year-old is considering a hair transplant to address diffuse thinning and is currently using oral finasteride and minoxidil, with plans to switch to oral dutasteride. They are debating between one or two procedures and are seeking advice on graft numbers and additional treatments like oils and micro-needling.

The user regrets not taking medication after a hair transplant and is now using finasteride and minoxidil to manage hair loss. They plan to have another transplant and continue medication for life.

A 30-year-old MTF individual shares their hair regrowth journey using feminizing HRT, Minoxidil, and occasional dermarolling, noting significant progress but acknowledging ongoing challenges with thin hair. They express hope for continued improvement and consider a future hair transplant if necessary.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

People shared regrets and advice about hair transplants, including timing the procedure in winter to avoid sun and sweat, and avoiding certain clinics. Some regretted specific methods like FUT due to visible scarring, while others warned against being influenced by social media.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

A user shared their positive experience with a hair transplant in Turkey using the DHI and Sapphire FUE techniques, without taking finasteride or minoxidil post-surgery. They emphasized that transplanted hairs from the donor area are resistant to hair loss, but acknowledged that native hairs might still thin without medication.

A user shared their successful 1-year update after a 2300 FUE hair transplant in Seoul, Korea, praising Dr. Ko's work for achieving a natural-looking hairline. The conversation includes admiration for the results and inquiries about the procedure's cost and requirements.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.